


FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT 	APPLICATION NO.: 09/954,987	ATTY. DOCKET NO.: C01041.70016 US
	FILING DATE: September 17, 2001	CONFIRMATION NO.: 7680
	APPLICANT: Bauer et al.	
	GROUP ART UNIT: 1645/631	EXAMINER: Not yet assigned Smith

Sheet 1 of 1

U.S. PATENT DOCUMENTS


Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS


Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
CS ↓	C38	AHMAD-NEJAD P et al., Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. <i>Eur J Immunol.</i> 2002 Jul;32(7):1958-68.	
	C39	KIRSCHNING CJ et al., Toll-like receptors: cellular signal transducers for exogenous molecular patterns causing immune responses. <i>Int J Med Microbiol.</i> 2001 Sep;291(4):251-60.	
	C40	LEIFER CA et al., Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. (ABSTRACT #117). Activating Immunity with CpG Oligos, 2 nd International Symposium, Amelia Island, Florida, October 7-10, 2001.	
	C41	TAKEUCHI O et al., Genetic approaches to the study of Toll-like receptor function. <i>Microbes Infect.</i> 2002 Jul;4(9):887-95.	
	C42	WAGNER H, Interactions between bacterial CpG-DNA and TLR9 bridge innate and adaptive immunity. <i>Curr Opin Microbiol.</i> 2002 Feb;5(1):62-9.	

EXAMINER 	DATE CONSIDERED 7/2/03
---	---------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]



FORM PTO 449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICATION NO.: 09/954,987		ATTY. DOCKET NO.: C01041.70016.US	
	FILING DATE: September 17, 2001		CONFIRMATION NO.: 7680	
	APPLICANT: Bauer et al.			
	GROUP ART UNIT: 1631		EXAMINER: Carolyn L. Smith	
Sheet	1	of	1	

U.S. PATENT DOCUMENTS


Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD- YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume- issue number(s), publisher, city and/or country where published.	Translation (Y/N)
CS	C43	CHUAN T-H et al., Toll-like receptor 9 mediates CpG-DNA signaling. <i>J Leukoc Biol.</i> 2002 Mar;71(3):538-44.	
	C44	GENBANK Accession No. AF348140, Mus musculus toll-like receptor 9 (Tlr9), mRNA, complete cds. April 5, 2001.	
	C45	HOSHINO K et al., Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. <i>J Immunol.</i> 1999 Apr 1;162(7):3749-52.	
	C46	KOPP EB et al. The Toll-receptor family and control of innate immunity. <i>Curr Opin Immunol.</i> 1999 Feb;11(1):13-8.	
	C47	MUZIO M et al., Toll-like receptors. <i>Microbes Infect.</i> 2000 Mar;2(3):251-5.	

EXAMINER 	DATE CONSIDERED 7/2/03
---	---------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

RECEIVED
FEB 10 2003
TECH CENTER 1600/2800


FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT JAN 08 2002 PATENT & TRADEMARK OFFICE		APPLICATION NO.: 09/954,987	ATTY. DOCKET NO.: C1041/7016
		FILING DATE: September 17, 2001	
		APPLICANT: Lipford et al.	
		GROUP ART UNIT: 1645-1631	EXAMINER: unknown Smith
Sheet	3		

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of Issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
CS	A1	5,567,604		Rando et al.	10-22-1996
	A2	5,663,153		Hutcherson et al.	09-02-1997
	A3	5,723,335		Hutcherson et al.	03-03-1998
	A4	6,013,639		Peyman et al.	01-11-2000
	A5	6,121,434		Peyman et al.	09-19-2000
	A6	6,194,388	B1	Krieg et al.	02-27-2001
	A7	6,207,646	B1	Krieg et al.	03-27-2001
	A8	6,214,806	B1	Krieg et al.	04-10-2001
	A9	6,218,371	B1	Krieg et al.	04-17-2001
	A10	6,239,116	B1	Krieg et al.	05-29-2001

FOREIGN PATENT DOCUMENTS


Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
CS	B1	EPO	EP1142472	A1		10-10-2001	
	B2	WIPO	WO94/29469	A2		12-22-1994	
	B3	WIPO	WO96/24380	A1		08-15-1996	
	B4	WIPO	WO96/2555	A1		02-01-1996	
	B5	WIPO	WO97/00957	A1		01-09-1997	
	B6	WIPO	WO98/18810	A1		05-07-1998	
	B7	WIPO	WO98/29430	A1		07-09-1998	
	B8	WIPO	WO98/32462	A1		07-30-1998	
	B9	WIPO	WO98/37919	A1		09-03-1998	
	B10	WIPO	WO98/40100	A1		09-17-1998	
	B11	WIPO	WO98/50547	A2		11-12-1998	
	B12	WIPO	WO98/52581	A1		11-26-1998	
	B13	WIPO	WO99/20756	A2		04-29-1999	
	B14	WIPO	WO99/51259	A2		10-14-1999	
	B15	WIPO	WO99/56755	A1		11-11-1999	
	B16	WIPO	WO99/58118	A2		11-18-1999	
	B17	WIPO	WO99/61056	A2		12-02-1999	
	B18	WIPO	WO00/06588	A1		02-10-2000	
	B19	WIPO	WO00/14217	A2		03-16-2000	
	B20	WIPO	WO00/67023	A1		11-09-2000	
	B21	WIPO	WO01/22972	A2		04-05-2001	
	B22	WIPO	WO01/22990	A2		04-05-2001	
	B23	WIPO	WO01/32877	A2		05-10-2001	
	B24	WIPO	WO01/55386	A1		08-02-2001	

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/954,987	ATTY. DOCKET NO.: C1041/7016
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		FILING DATE: September 17, 2001	
		APPLICANT: Lipford et al.	
		GROUP ART UNIT: 1645-1631	EXAMINER: unknown Smith
Sheet	2	3	


OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
CS	C1	ADEREM A et al., Toll-like receptors in the induction of the innate immune response. <i>Nature</i> . 2000 Aug 17;406(6797):782-7.	
	C2	AGRAWAL A et al., Transposition mediated by RAG1 and RAG2 and its implications for the evolution of the immune system. <i>Nature</i> . 1998 Aug 20;394(6695):744-51.	
	C3	BAUER S et al., Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. <i>Proc Natl Acad Sci USA</i> . 2001 Jul 31;98(16):9237-42.	
	C4	CHAUDHARY PM et al., Cloning and characterization of two Toll/Interleukin-1 receptor-like genes TIL3 and TIL4: evidence for a multi-gene receptor family in humans. <i>Blood</i> . 1998 Jun 1;91(11):4020-7.	
	C5	CHUANG TH et al., Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. <i>Eur Cytokine Netw</i> . 2000 Sep;11(3):372-8.	
	C6	DEMOULIN JB et al., A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9. <i>Mol Cell Biol</i> . 1996 Sep;16(9):4710-6.	
	C7	DU X et al., Three novel mammalian toll-like receptors: gene structure, expression, and evolution. <i>Eur Cytokine Netw</i> . 2000 Sep;11(3):362-71.	
	C8	EDEN CS et al., Host resistance to mucosal gram-negative infection. Susceptibility of lipopolysaccharide nonresponder mice. <i>J Immunol</i> . 1988 May 1;140(9):3180-5.	
	C9	FEARON DT et al, The instructive role of innate immunity in the acquired immune response. <i>Science</i> . 1996 Apr 5;272(5258):50-3.	
	C10	FUJITA N et al., Mechanism of transcriptional regulation by methyl-CpG binding Protein MBD1, <i>Mol Cell Biol</i> 20:5107-18 (2000).	
	C11	HACKER H et al., Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells. <i>EMBO J</i> . 1999 Dec 15;18(24):6973-82.	
	C12	HACKER H et al., CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. <i>EMBO J</i> . 1998 Nov 2;17(21):6230-40.	
	C13	HACKER H et al., Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. <i>J Exp Med</i> . 2000 Aug 21;192(4):595-600.	
	C14	HEMMI H et al., A Toll-like receptor recognizes bacterial DNA. <i>Nature</i> . 2000 Dec 7;408(6813):740-5.	
	C15	HOFFMANN JA et al., Phylogenetic perspectives in innate immunity. <i>Science</i> . 1999 May 21;284(5418):1313-8.	
	C16	JANEWAY CA Jr., Approaching the asymptote? Evolution and revolution in immunology. <i>Cold Spring Harb Symp Quant Biol</i> . 1989;54 Pt 1:1-13.	
	C17	KIRSCHNING CJ et al., Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide. <i>J Exp Med</i> . 1998 Dec 7;188(11):2091-7.	
	C18	KRIEG AM et al., Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. <i>Immunol Today</i> . 2000 Oct;21(10):521-6.	
	C19	KRIEG AM et al., CpG motifs in bacterial DNA trigger direct B-cell activation. <i>Nature</i> . 1995 Apr 6;374(6522):546-9.	
	C20	LIANG H et al., Activation of human B cells by phosphorothioate oligodeoxynucleotides. <i>J Clin Invest</i> . 1996 Sep 1;98(5):1119-29.	
	C21	MACFARLANE DE et al., Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. <i>J Immunol</i> . 1998 Feb 1;160(3):1122-31.	
	C22	MANZEL L et al., Lack of immune stimulation by immobilized CpG-oligodeoxynucleotide. <i>Antisense Nucleic Acid Drug Dev</i> . 1999 Oct;9(5):459-64.	

RECEIVED
JAN 10 2002
TECH CENTER 1600/2900

FORM PTO-1449/A and B (Modified)		APPLICATION NO.: 09/954,987	ATTY. DOCKET NO.: C1041/7016
INFORMATION DISCLOSURE STATEMENT BY APPLICANT 		FILING DATE: September 17, 2001	
		APPLICANT: Lipford et al.	
		GROUP ART UNIT: 1645 1631	EXAMINER: unknown Smith
Sheet	3		

CS	C23	MEANS TK et al., Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. <i>J Immunol.</i> 1999 Oct 1;163(7):3920-7.		
	C24	MEDZHITOV R et al., A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. <i>Nature.</i> 1997 Jul 24;388(6640):394-7.		
	C25	MEDZHITOV R et al., Innate immunity: the virtues of a nonclonal system of recognition. <i>Cell.</i> 1997 Oct 31;91(3):295-8.		
	C26	MUZIO M et al., The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). <i>J Exp Med.</i> 1998 Jun 15;187(12):2097-101.		
	C27	MUZIO M et al., Toll-like receptors: a growing family of immune receptors that are differentially expressed and regulated by different leukocytes. <i>J Leukoc Biol.</i> 2000 Apr;67(4):450-6.		
	C28	OHKI I et al., Solution structure of the methyl-CpG-binding domain of the methylation-dependent transcriptional repressor MBD1. <i>EMBO J.</i> 1999 Dec 1;18(23):6653-61.		
	C29	POLTORAK A et al., Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. <i>Science.</i> 1998 Dec 11;282(5396):2085-8.		
	C30	QURESHI ST et al., Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). <i>J Exp Med.</i> 1999 Feb 15;189(4):615-25.		
	C31	ROCK FL et al., A family of human receptors structurally related to Drosophila Toll. <i>Proc Natl Acad Sci USA.</i> 1998 Jan 20;95(2):588-93.		
	C32	STRATFORD-PERRICAUDET LD et al., Widespread long-term gene transfer to mouse skeletal muscles and heart. <i>J Clin Invest.</i> 1992 Aug;90(2):626-30.		
	C33	TAKEUCHI O et al., TLR6: A novel member of an expanding toll-like receptor family. <i>Gene.</i> 1999 Apr 29;231(1-2):59-65.		
	C34	WAGNER H, Bacterial CpG DNA activates immune cells to signal infectious danger. <i>Adv Immunol.</i> 1999;73:329-68.		
	C35	YAMAMOTO S et al., DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. <i>Microbiol Immunol.</i> 1992;36(9):983-97.		
	C36	YAMAMOTO T et al., Lipofection of synthetic oligodeoxyribonucleotide having a palindromic sequence of AACGTT to murine splenocytes enhances interferon production and natural killer activity. <i>Microbiol Immunol.</i> 1994;38(10):831-6.		
✓	C37	YI AK et al., CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. <i>J Immunol.</i> 1998 May 15;160(10):4755-61.		

EXAMINER		DATE CONSIDERED	7/2/03
----------	---	-----------------	--------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]